The DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.
Effect of Genetic Differences in Omeprazole Metabolism on Cure Rates for Helicobacter pylori Infection and Peptic Ulcer
Abstract
BACKGROUND: Omeprazole is metabolized by S-mephenytoin 4'-hydroxylase (CYP2C19) in the liver. In persons with a poor-metabolizer genotype for CYP2C19, the therapeutic efficacy of omeprazole may be increased. OBJECTIVE: To investigate whether CYP2C19 genotype status is associated with cure rates for Helicobacterpylori infection and peptic ulcer achieved by using dual therapy with omeprazole and amoxicillin. DESIGN: Prospective cohort study. SETTING: University hospital and health service center in Hamamatsu, Japan. PATIENTS: 62 patients with peptic ulcer and H. pylori infection. INTERVENTION: Omeprazole and amoxicillin. MEASUREMENTS: CYP2C19 genotype status and cure rates for H. pylori infection and peptic ulcer. RESULTS: Cure rates for H. pylori infection were 28.6% (95% CI, 13.1% to 48.7%), 60% (CI, 38.6% to 83.0%), and 100% (CI, 66.4% to 100%) in the rapid-, intermediate-, and poor-metabolizer groups, respectively. Healing rates for both duodenal and gastric ulcer in the three groups were roughly parallel with cure rates for H. pylori infection. CONCLUSION: The results of the genotyping test for CYP2C19 seem to predict cure of H. pylori infection and peptic ulcer in patients who receive dual therapy with omeprazole and amoxicillin.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The major genetic defect responsible for the polymorphism of S-mephenytoin metabolism in humans.
de Morais, S. M., Wilkinson, G. R., Blaisdell, J., Nakamura, K., Meyer, U. A., & Goldstein, J. A. (1994) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)40694-6 · Cited by 956
De Morais, S. M., Wilkinson, G. R., Blaisdell, J., Meyer, U. A., Nakamura, K., & Goldstein, J. A. (1994) · Molecular Pharmacology · doi:10.1016/s0026-895x(25)09788-3 · Cited by 752
The Treatment of Helicobacter pylori Infection in the Management of Peptic Ulcer Disease
Walsh, J. H., & Peterson, W. L. (1995) · New England Journal of Medicine · doi:10.1056/nejm199510123331508 · Cited by 383
Genotyping of S-mephenytoin 4′-hydroxylation in an extended Japanese population*
Kubota, T., Chiba, K., & Ishizaki, T. (1996) · Clinical Pharmacology & Therapeutics · doi:10.1016/s0009-9236(96)90214-3 · Cited by 288
Self-citationMedical Treatment of Peptic Ulcer Disease: Practice Guidelines
Soll, A. H. (1996) · JAMA · doi:10.1001/jama.1996.03530320046033 · Cited by 259
Peterson, W. L., Graham, D. Y., Marshall, B. J., Blaser, M. J., Genta, R. M., Klein, P., Stratton, C. W., Drnec, J., Prokocimer, P., & Siepman, N. Y. (1993) · PubMed · Cited by 229
Goddard, A., Jessa, M., Barrett, D., Shaw, P., Idstrom, J., Cederberg, C., & Spiller, R. (1996) · Gastroenterology · doi:10.1053/gast.1996.v111.pm8690200 · Cited by 218
Goodwin, C. S., Mendall, M. M., & Northfield, T. C. (1997) · The Lancet · doi:10.1016/s0140-6736(96)07023-7 · Cited by 212
Bayerdörffer, E., Miehlke, S., Mannes, G. A., Sommer, A., Höchter, W., Weingart, J., Heldwein, W., Klann, H., Simon, T., Schmitt, W., et al. (1995) · Gastroenterology · doi:10.1016/0016-5085(95)90689-4 · Cited by 211
Chang, M., Tybring, G., Dahl, M., Gotharson, E., Sagar, M., Seensalu, R., & Bertilsson, L. (1995) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.1995.tb04488.x · Cited by 184
Cited by
Zanger, U. M., & Schwab, M. (2013) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2012.12.007 · Cited by 4,169
“Since CYP2C19 contributes significantly to the metabolism of the PPIs omeprazole, lansoprazole, and pantoprazole and to minor extent to the metabolism of rabeprazole, pharmacokinetics, the PPI-induced increase in intragastric pH and treatment outcome depend on CYP2C19 genotype (Furuta et al., 1998; Klotz et al., 2004;…”
BackgroundManagement of Helicobacter pylori infection—the Maastricht V/Florence Consensus Report
Malfertheiner, P., Megraud, F., O'Morain, C. A., Gisbert, J. P., Kuipers, E. J., Axon, A. T., Bazzoli, F., Gasbarrini, A., Atherton, J., Graham, D. Y., et al. (2017) · Gut · doi:10.1136/gutjnl-2016-312288 · Cited by 2,946
Drug Metabolism and Variability among Patients in Drug Response
Wilkinson, G. R. (2005) · New England Journal of Medicine · doi:10.1056/nejmra032424 · Cited by 1,185
Weinshilboum, R. (2003) · New England Journal of Medicine · doi:10.1056/nejmra020021 · Cited by 1,031
Clinical Significance of the Cytochrome P450 2C19 Genetic Polymorphism
Desta, Z., Zhao, X., Shin, J.-G., & Flockhart, D. A. (2002) · Clinical Pharmacokinetics · doi:10.2165/00003088-200241120-00002 · Cited by 942
Metadata
- Authors
- Furuta, T., Ohashi, K., Kamata, T., Takashima, M., Kosuge, K., Kawasaki, T., Hanai, H., Kubota, T., Ishizaki, T., & Kaneko, E.
- Venue
- Annals of Internal Medicine
- Publisher
- American College of Physicians
- Published
- 1998-12-15
- Volume
- 129
- Issue
- 12
- Pages
- 1027-1030
- ISSN
- 0003-4819 (ISSN-L)
- 1539-3704
- OpenAlex
- W2094722170
- Cited by
- 335
- References
- 15
- FWCI
- 17.39
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Effect of Genetic Differences in Omeprazole Metabolism on Cure Rates for Helicobacter pylori Infection and Peptic Ulcer. https://app.cochat.ai/papers/10.7326/0003-4819-129-12-199812150-00006
- The paper
- Furuta, T., Ohashi, K., Kamata, T., Takashima, M., Kosuge, K., Kawasaki, T., Hanai, H., Kubota, T., Ishizaki, T., & Kaneko, E. (1998). Effect of Genetic Differences in Omeprazole Metabolism on Cure Rates for Helicobacter pylori Infection and Peptic Ulcer. Annals of Internal Medicine. https://doi.org/10.7326/0003-4819-129-12-199812150-00006
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.